Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) — Tangible Net Worth Ratio
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) has a Tangible Net Worth Ratio of 96.0% as of June 2025. This metric is calculated by deducting intangible assets ($95.61 Million) from net assets ($2.39 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Shanghai Shenqi Pharmaceutical Investmen (900904) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Tangible Net Worth Ratio (2015–2024)
This chart shows how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's Tangible Net Worth Ratio has changed across 10 annual periods from 2015 to 2024. As of June 2025, the ratio stands at 96.0%, reflecting net assets of $2.39 Billion with intangible assets of $95.61 Million USD. See Shanghai Shenqi Pharmaceutical Investmen defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (2015–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B from 2015 to 2024, covering 10 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market value of Shanghai Shenqi Pharmaceutical Investmen.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 96.0% | $2.43 Billion | $96.65 Million | $3.12 Billion | ▼ 0.0 pp |
| 2023 | 96.0% | $2.39 Billion | $95.20 Million | $3.28 Billion | ▲ +0.2 pp |
| 2022 | 95.8% | $2.37 Billion | $98.91 Million | $3.39 Billion | ▲ +0.2 pp |
| 2021 | 95.6% | $2.39 Billion | $104.81 Million | $3.15 Billion | ▲ +0.4 pp |
| 2020 | 95.2% | $2.33 Billion | $110.66 Million | $3.10 Billion | ▼ -0.3 pp |
| 2019 | 95.6% | $2.66 Billion | $118.00 Million | $3.56 Billion | ▲ +0.4 pp |
| 2018 | 95.2% | $2.60 Billion | $124.72 Million | $3.13 Billion | ▼ 0.0 pp |
| 2017 | 95.2% | $2.53 Billion | $121.11 Million | $3.10 Billion | ▼ -0.2 pp |
| 2016 | 95.4% | $2.43 Billion | $112.76 Million | $3.00 Billion | ▲ +0.1 pp |
| 2015 | 95.3% | $2.29 Billion | $107.92 Million | $2.67 Billion | — |